Abstract:Background COVID-19 has been widely spreading. We aim to examine adaptive immune cells in non-severe patients with persistent SARS-CoV-2 shedding. Methods 37 non-severe patients with persistent SARS-CoV-2 presence transferred to Zhongnan hospital of Wuhan University were retrospectively recruited to PP (persistently positive) group, which was further allocated to PPP group (n=19) and PPN group (n=18), according to their testing results after 7 days (N=negative). Epidemiological, demographic, clinical and laboratory data were collected and analyzed. Data from age- and sex-matched non-severe patients at disease onset (PA [positive on admission] patients, n=37), and lymphocyte subpopulation measurements from matched 54 healthy subjects were extracted for comparison. Results Compared with PA patients, PP patients had much improved laboratory findings, including WBCs, neutrophils, lymphocytes, neutrophil-to-lymphocyte ratio, albumin, AST, CRP, SAA, and IL-6. The absolute numbers of CD3+ T cells, CD4+ T cells, and NK cells were significantly higher in PP group than that in PA group, and were comparable to that in healthy controls. PPP subgroup had markedly reduced B cells and T cells compared to PPN group and healthy subjects. Finally, paired results of these lymphocyte subpopulations from 10 PPN patients demonstrated that the number of T cells and B cells significantly increased when the SARS-CoV-2 tests turned negative. Conclusion Persistent SARS-CoV-2 presence in non-severe COVID-19 patients is associated with reduced numbers of adaptive immune cells. Monitoring lymphocyte subpopulations could be clinically meaningful in identifying fully recovered COVID-19 patients. Summary Defects in adaptive immune system, including reduced T cells and B cells, were frequently observed in non-severe COVID-19 patients with persistent SARS-CoV-2 shedding. Assessment of immune system could be clinically relevant for discharge management. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This work was supported by the National Natural Science Foundation of China (2017NSFC81670825 to Y.H. and 2020NSFC31970865 to J.H.), Natural Science Foundation of Hubei Province (2017CFB512 to B.L.), and Science and Technology Innovation Cultivation Foundation of Zhongnan Hospital of Wuhan University (ZNPY2018107 to B.L.). ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes After publication, the data will be made available to others on reasonable requests to the corresponding author. A proposal with detailed description of study objectives and statistical analysis plan will be needed for evaluation of the reasonability of requests. Additional materials might also be required during the process of evaluation. Deidentified participant data will be provided after approval from the corresponding author and Zhongnan Hospital of Wuhan University. * COVID-19 : Coronavirus disease 2019 SARS-CoV-2 : Severe acute respiratory syndrome coronavirus 2 HC : Healthy controls

Characteristics of T‐cell Responses in COVID‐19 Patients with Prolonged SARS‐CoV‐2 Positivity – a Cohort Study

Alterations in Phenotypes and Responses of T Cells Within 6 Months of Recovery from COVID-19: A Cohort Study

Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19)

Clinical and Molecular Characteristics of COVID-19 Patients with Persistent SARS-CoV-2 Infection

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Longitudinal Characteristics of T Cell Responses in Asymptomatic SARS-CoV-2 Infection

Broad phenotypic alterations and potential dysfunctions of lymphocytes in COVID-19 recovered individuals

Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals

Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study

Longitudinal Dynamics of Cellular Responses in Recovered COVID-19 Patients

Immune Responses in Discharged COVID-19 Patients With and Without Long COVID Symptoms

Single-cell landscape of immunological responses in patients with COVID-19

Dynamic changes in lymphocyte subsets and parallel cytokine levels in patients with severe and critical COVID-19

Longitudinal transcriptome analyses show robust T cell immunity during recovery from COVID-19

Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease

High Levels of Circulating IL-8 and Soluble IL-2R Are Associated With Prolonged Illness in Patients With Severe COVID-19

Longitudinal Peripheral Blood Transcriptional Analysis Reveals Molecular Signatures of Disease Progression in COVID-19 Patients

Delayed bystander CD8 T cell activation, early immune pathology and persistent dysregulation characterise severe COVID-19

Persistent SARS-CoV-2 presence is companied with defects in adaptive immune system in non-severe COVID-19 patients

An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease

Broad phenotypic alterations and potential dysfunction of lymphocytes in individuals clinically recovered from COVID-19